Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Pipeline Review, H2 2018

Publication ID:
GMD0818127

Publication Date:
August 21, 2018

Pages:
93

Publisher:
Global Markets Direct

Region:
Global [1]

$3,500.00

Publication License Type *
○ Single User License (PDF), $3,500.00

○ Site License (PDF), $7,000.00

○ Global License (PDF), $10,500.00

Please choose the suitable license type from above. More details are at given under tab "Report License Types" below.
Description:
Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Pipeline Review, H2 2018

Summary

According to the recently published report ‘Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Pipeline Review, H2 2018’; Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) pipeline Target constitutes close to 30 molecules. Out of which approximately 27 molecules are developed by companies and remaining by the universities/institutes.

Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Soluble guanylyl cyclase (sGC) is the known receptor for nitric oxide. Binding of nitric oxide to the heme moiety of the cyclase induces its capacity to synthesize the second messenger cGMP. Although the changes in the state of the heme moiety upon exposure of enzyme to NO and its correlation to the stimulation of sGC catalytic activity.

The report ‘Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Pipeline Review, H2 2018’ outlays comprehensive information on the Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 3, 6, 3 and 15 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.

Report covers products from therapy areas Ophthalmology, Cardiovascular, Metabolic Disorders, Respiratory, Central Nervous System, Gastrointestinal, Hematological Disorders, Immunology, Infectious Disease, Oncology, Dermatology, Genetic Disorders, Genito Urinary System And Sex Hormones and Toxicology which include indications Glaucoma, Ocular Hypertension, Diabetic Nephropathy, Open-Angle Glaucoma, Pulmonary Hypertension, Sickle Cell Disease, Tinea Pedis (Athlete Foot), Acute Respiratory Distress Syndrome, Alzheimer's Disease, Carotid Artery Stenosis, Chemotherapy Induced Peripheral Neuropathy, Chronic Kidney Disease (Chronic Renal Failure), Cystic Fibrosis, Diabetic Foot Ulcers, Diabetic Neuropathic Pain, Diastolic Heart Failure, Duchenne Muscular Dystrophy, Esophageal Achalasia, Inflammation, Ischemic Stroke, Liver Diseases, Lung Disease, Mycobacterium Infections, Onychomycosis (Tinea Unguium), Optic Neuropathy, Osteoporosis, Pancreatic Cancer, Prostate Cancer, Pulmonary Arterial Hypertension, Stroke, Systemic Sclerosis (Scleroderma), Systolic Heart Failure, Vascular Dementias and Wounds.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
- The report provides a snapshot of the global therapeutic landscape for Soluble Guanylate Cyclase (sGC or EC 4.6.1.2)
- The report reviews Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) targeted therapeutics and enlists all their major and minor projects
- The report assesses Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) targeted therapeutics

Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Soluble Guanylate Cyclase (sGC or EC 4.6.1.2)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table Of Contents:
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Overview
Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Companies Involved in Therapeutics Development
Bayer AG
Boehringer Ingelheim GmbH
Ironwood Pharmaceuticals Inc
NicOx SA
Novan Inc
Novartis AG
SynZyme Technologies LLC
Topadur Pharma AG
Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Drug Profiles
A-8R - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BAY-1101042 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BAY-1237592 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BAY-546544 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BI-703704 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
olinciguat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
praliciguat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Q-201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
riociguat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Activate sGC for Osteoporosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Activate Soluble Guanylate Cyclase for Acute Respiratory Distress Syndrome - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Activate Soluble Guanylate Cyclase for Glaucoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Activate Soluble Guanylate Cyclase for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Activate sGC for Liver Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Activate sGC for Lung Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TOPN-53 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vacno - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
vericiguat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Dormant Products
Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Discontinued Products
Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Product Development Milestones
Featured News & Press Releases
Aug 06, 2018: Nicox starts Phase II trial of NCX 470 against latanoprost 0.005%
Jun 23, 2018: Ironwood Presents Praliciguat Phase IIa Study Data Showing Positive Impact on Metabolic and Cardiovascular Clinical Endpoints at the American Diabetes Association’s 78th Scientific Sessions
Jun 20, 2018: Ironwood Pharmaceuticals to Highlight Clinical and Preclinical Data for Praliciguat at the American Diabetes Association’s 78th Scientific Sessions
Jun 07, 2018: Ironwood Pharmaceuticals Announces FDA Orphan Drug Designation for Olinciguat for the Treatment of Sickle Cell Disease
May 17, 2018: SB208 Increases Daily Nail Growth Rate over Four Weeks of Treatment
May 03, 2018: Nicox announces the presentation of scientific data for NCX 667 at ARVO 2018
Jan 11, 2018: Novan to Present Positive Phase 2 Results for SB208 Antifungal Program at Winter Clinical Dermatology Conference
Dec 21, 2017: Ironwood Pharmaceuticals Initiates Phase II Clinical Trial of sGC Stimulator IW-1701 in Patients with Sickle Cell Disease
Dec 04, 2017: Ironwood Reports Top-line Phase IIa Data for IW-1973 Demonstrating Positive Cardiovascular, Metabolic and Endothelial Effects
Oct 31, 2017: Novoteris Investigator Receives Health Canada Clearance to Start a Phase 2a Clinical Trial of its Thiolanox® Nitric Oxide for the Treatment of Non-Tuberculous Mycobacteria
Oct 24, 2017: Bayer to Present Pulmonary Arterial Hypertension Data at the 2017 Annual Meeting of the American College of Chest Physicians
Jun 29, 2017: Bayer Now Enrolling Patients into a Global Pulmonary Arterial Hypertension Study
Jun 05, 2017: Novoteris Receives FDA and Health Canada Clearance to Start a Phase 2 Clinical Trial of its Thiolanox Nitric Oxide for the Treatment of Cystic Fibrosis

May 19, 2017: Bayer to Present Pulmonary Hypertension Data at the American Thoracic Society 2017 International Conference

May 09, 2017: Nicox announces the presentation of scientific data on NCX 667 at ARVO 2017

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Indications, H2 2018

Number of Products under Development by Indications, H2 2018 (Contd..1), H2 2018

Number of Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Products under Development by Companies, H2 2018 (Contd..2), H2 2018

Number of Products under Investigation by Universities/Institutes, H2 2018

Products under Investigation by Universities/Institutes, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Pipeline by Bayer AG, H2 2018

Pipeline by Boehringer Ingelheim GmbH, H2 2018

Pipeline by Ironwood Pharmaceuticals Inc, H2 2018

Pipeline by NicOx SA, H2 2018

Pipeline by Novan Inc, H2 2018

Pipeline by Novartis AG, H2 2018

Pipeline by SynZyme Technologies LLC, H2 2018

Pipeline by Topadur Pharma AG, H2 2018

Dormant Products, H2 2018

Dormant Products, H2 2018 (Contd..1), H2 2018

Dormant Products, H2 2018 (Contd..2), H2 2018
Dormant Products, H2 2018 (Contd..3), H2 2018
Discontinued Products, H2 2018

List of Figures
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018

Companies Mentioned:
Bayer AG
Boehringer Ingelheim GmbH
Ironwood Pharmaceuticals Inc
NicOx SA
Novan Inc
Novartis AG
SynZyme Technologies LLC
Topadur Pharma AG

License Types:

Single User License (PDF)

- This license allows for use of a publication by one person.
- This person may print out a single copy of the publication.
- This person can include information given in the publication in presentations and internal reports by
  providing full copyright credit to the publisher.
- This person cannot share the publication (or any information contained therein) with any other
  person or persons.
- Unless a Enterprise License is purchased, a Single User License must be purchased for every person
  that wishes to use the publication within the same organization.
- Customers who infringe these license terms are liable for a Global license fee.

Site License (PDF)
This license allows for use of a publication by all users within one corporate location, e.g. a regional office.

These users may print out a single copy of the publication.

These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.

Unless an Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.

Customers who infringe these license terms are liable for a Global license fee.

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.

Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.

These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.
RECENT POSTS

What is drug pipeline research?
March 20

How to use market research to bring your idea to life?
March 11

How to gain business insights using syndicated market research?
March 10

Source URL: https://www.drugpipeline.net/global-markets-direct/soluble-guanylate-cyclase-sgc-or-ec-4612-pipeline-review-h2-2018

Links
[1] https://www.drugpipeline.net/region/global